|
|
|
Volumn 118, Issue 1227, 2005, Pages
|
|
PHARMAC responds on TNF inhibitors for inflammatory arthritis.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRHEUMATIC AGENT;
TUMOR NECROSIS FACTOR ALPHA;
COST BENEFIT ANALYSIS;
DRUG ANTAGONISM;
DRUG APPROVAL;
DRUG SCREENING;
ECONOMICS;
HUMAN;
METHODOLOGY;
NEW ZEALAND;
NOTE;
PATIENT SELECTION;
PUBLIC HEALTH;
RHEUMATOID ARTHRITIS;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
COST-BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG EVALUATION;
HUMANS;
NATIONAL HEALTH PROGRAMS;
NEW ZEALAND;
PATIENT SELECTION;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 33644817228
PISSN: None
EISSN: 11758716
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
